Longevity & AgingPSA Screening Cuts Prostate Cancer Deaths, Major Cochrane Review Confirms
A new Cochrane review — one of the most rigorous types of scientific evidence summaries — analyzed six large trials involving 800,000 men across Europe and North America. Researchers found with moderate certainty that PSA blood screening reduces deaths from prostate cancer. The benefit, while real, is modest: approximately two fewer prostate cancer deaths per 1,000 men screened. PSA testing measures a protein produced by the prostate gland, with elevated levels potentially signaling cancer. This review marks a meaningful shift in medical consensus, as earlier evidence was more ambiguous. For health-conscious men, particularly those over 50 or with elevated risk factors, this finding strengthens the case for discussing PSA screening with a physician as part of a proactive longevity strategy.
